PONVORY™ (ponesimod) HCP
PONVORY™ WAS PROVEN SUPERIOR AT REDUCING RELAPSES AND LESIONS VS AUBAGIO® IN A STUDY LASTING ~2 YEARS1
PONVORY™: a new oral, once-daily, selective S1P1 therapy for relapsing MS in adults1-3*
No genetic testing; no first-dose monitoring for most patients‡; no known food restrictions; ~7-day reversibility of lymphocyte count reduction, as seen in PK-PD assessments; 1-week elimination allows for pregnancy 7 days after stopping PONVORY™; no rapid elimination procedure required1
ARR = annualized relapse rate; GdE = gadolinium-enhancing; PD = pharmacodynamic; PK = pharmacokinetic; S1P1 = sphingosine-1-phosphate 1.
*The exact mechanism by which PONVORY™ exerts therapeutic effects in MS is unknown but may involve reduction of lymphocyte migration into the central nervous system.1
†As studied in OPTIMUM, a 108-week, randomized, double-blind, phase 3 study.1
‡First-dose, 4-hour monitoring is recommended for patients with sinus bradycardia (heart rate <55 beats per minute), first- or second-degree atrioventricular block (Mobitz type I), or a history of myocardial infarction or heart failure occurring >6 months prior to treatment initiation and in stable condition.1